Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers
暂无分享,去创建一个
S. Fröhling | D. Jäger | A. Mock | C. Flechtenmacher | K. Zaoui | K. Freier | J. Hess | J. Krauss | J. Hoffmann | C. Freudlsperger | D. Horn | J. Moratin | K. Metzger | Sonja Obradovic
[1] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[2] Zhenggang Chen,et al. Diagnostic and therapeutic role of microRNAs in oral cancer , 2020, Oncology reports.
[3] E. Jaffee,et al. Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis , 2020, Clinical Cancer Research.
[4] P. Ramos-García,et al. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. , 2020, Oral oncology.
[5] R. Eils,et al. Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer , 2020, Clinical Cancer Research.
[6] A. Mäkitie,et al. Overall assessment of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: time to take notice , 2020, Acta oto-laryngologica.
[7] P. Ettmayer,et al. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance , 2020, Molecular Cancer Therapeutics.
[8] J. Rajguru,et al. Tumor markers in oral cancer: A review , 2020, Journal of family medicine and primary care.
[9] C. R. Leemans,et al. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors , 2020, Cancer Immunology, Immunotherapy.
[10] Hung-Ming Wang,et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.
[11] Victoria Sanz-Moreno,et al. Faculty Opinions recommendation of QuPath: Open source software for digital pathology image analysis. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[12] Nasir M. Rajpoot,et al. A Novel Digital Score for Abundance of Tumour Infiltrating Lymphocytes Predicts Disease Free Survival in Oral Squamous Cell Carcinoma , 2019, Scientific Reports.
[13] E. Herpel,et al. Upregulation of PD‐L1 and PD‐L2 in neck node metastases of head and neck squamous cell carcinoma , 2019, Head & neck.
[14] T. Salo,et al. Assessment of Tumor-infiltrating Lymphocytes Predicts the Behavior of Early-stage Oral Tongue Cancer , 2019, The American journal of surgical pathology.
[15] C. von Buchwald,et al. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma , 2019, British Journal of Cancer.
[16] C. Brennan,et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.
[17] O. V. Matorin,et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.
[18] M. Salto‐Tellez,et al. Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer , 2018, Journal of oncology.
[19] A. Gonzalez-Perez,et al. NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival , 2018, Clinical Cancer Research.
[20] Juan Shen,et al. Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma. , 2018, Human pathology.
[21] M. Najafi,et al. Cyclooxygenase‐2 in cancer: A review , 2018, Journal of cellular physiology.
[22] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[23] H. Woodrow,et al. : A Review of the , 2018 .
[24] E. Richardsen,et al. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer. , 2018, Human pathology.
[25] P. Ferroli,et al. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide , 2017, Oncoimmunology.
[26] K. Jakubowska,et al. Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma , 2017, Oncology letters.
[27] P. Pharoah,et al. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer , 2017, BMC Cancer.
[28] K. Harrington,et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. , 2017, The Lancet. Oncology.
[29] Laurence Zitvogel,et al. The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.
[30] Zhengxue Han,et al. Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma , 2016, Translational oncology.
[31] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.
[32] J. Lunceford,et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.
[33] Sudeep Gupta,et al. Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer. , 2015, The New England journal of medicine.
[34] R. Childs,et al. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens , 2015, Nature Reviews Drug Discovery.
[35] Zhao Lu,et al. Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis , 2014, Tumor Biology.
[36] C. Rödel,et al. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer , 2014, Oncoimmunology.
[37] F. Marincola,et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.
[38] E. King,et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer , 2013, British Journal of Cancer.
[39] C. Rödel,et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer , 2013, British Journal of Cancer.
[40] J. Galon,et al. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. , 2013, Current opinion in immunology.
[41] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[42] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[43] M. Caligiuri,et al. Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.
[44] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[45] M. Karamouzis,et al. Faculty Opinions recommendation of Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009 .
[46] J. Pignon,et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[47] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[48] M. Caligiuri,et al. Human natural killer cells. , 2008, Blood.
[49] F. Schmidt. Meta-Analysis , 2008 .
[50] M. Ikram,et al. Neck involvement in early carcinoma of tongue. Is elective neck dissection warranted? , 2007, JPMA. The Journal of the Pakistan Medical Association.
[51] Axel Benner,et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. , 2003, Cancer research.
[52] D. Sidransky,et al. Head and neck cancer. , 2001, The New England journal of medicine.
[53] R. Lima,et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. , 1994, American journal of surgery.
[54] Jian-yong Li,et al. Low absolute NK cell counts in peripheral blood are associated with inferior survival in patients with mantle cell lymphoma. , 2019, Cancer biomarkers : section A of Disease markers.
[55] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[56] Jacques Ferlay,et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012 , 2017, CA: a cancer journal for clinicians.
[57] 藤倉雄二,et al. わが国における成人市中肺炎原因微生物についてのsystematic review/meta‐analysis , 2016 .
[58] Rbcafe. The Force Awakens , 2015 .
[59] R. Singh,et al. Demographic risk factors, affected anatomical sites and clinicopathological profile for oral squamous cell carcinoma in a north Indian population. , 2014, Asian Pacific journal of cancer prevention : APJCP.